WA
GNMX

WFG Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

WFG Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-20,000
Closed -$101K – 2149
2014
Q4 		$101K Hold
20,000
– – 0.02% 633
2014
Q3 		$104K Hold
20,000
– – 0.02% 654
2014
Q2 		$155K Buy
20,000
+5,400
+37% +$38.1K 0.03% 516
2014
Q1 		$102K Buy
14,600
+4,600
+46% +$35.9K 0.02% 634
2013
Q4 		$60K Buy
+10,000
New +$65.4K 0.01% 931

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

WFG Advisors's GNMX Position: Q1 2015 in Review

WFG Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2015, closing a stake of 20,000 shares — an estimated $101K sold.

WFG Advisors first reported a position in GNMX in Q4 2013 and held it in 5 quarters. The position peaked at $155K in Q2 2014. 43 funds tracked by Wall St. Rank hold GNMX as of Q1 2015.

  • WFG Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q1 2015 after selling out during the quarter.
  • WFG Advisors sold 20,000 Aevi Genomic Medicine Inc shares in Q1 2015, an estimated $101K.
  • WFG Advisors first reported a position in Aevi Genomic Medicine Inc in Q4 2013 and held it in 5 quarters.
  • WFG Advisors's Aevi Genomic Medicine Inc position peaked at $155K in Q2 2014.
  • 43 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2015.

Based on WFG Advisors's 13F filing for Q1 2015, filed 12 May 2015.